STAGE IV RENAL CELL CANCER AJCC V8
Clinical trials for STAGE IV RENAL CELL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV RENAL CELL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV RENAL CELL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for tough kidney cancer
Disease control OngoingThis study tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will receive either the usual treatment or the usual …
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
Promising combo aims to ease bone pain in advanced kidney cancer
Disease control OngoingThis study tests whether adding a radioactive drug (radium-223) to standard treatment (cabozantinib) helps people with advanced kidney cancer that has spread to the bones. About 134 participants will receive either the combination or cabozantinib alone. The goal is to see if the …
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a ZAP of radiation before standard care beat back metastatic kidney cancer?
Disease control OngoingThis Phase III trial tests whether giving a highly targeted form of radiation (SAbR) before standard therapy (immunotherapy or targeted pills) helps people with kidney cancer that has spread to 2-5 spots in the body live longer. About 472 participants are randomly assigned to rec…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare kidney cancer: drug combo shows promise
Disease control OngoingThis study tests whether combining two drugs—axitinib (which blocks cancer growth) and nivolumab (which helps the immune system fight cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes about …
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New study tests aggressive BP management to protect heart and kidneys in cancer patients
Disease control OngoingThis phase II trial tests whether intensive blood pressure management (targeting systolic BP below 120 mmHg) is better than standard care (below 140 mmHg) for patients with advanced kidney or thyroid cancer starting anti-angiogenic TKI therapy. The study enrolls 61 participants a…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: NA • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets Hard-to-Treat cancers with rare gene flaw
Disease control OngoingThis study tests a drug called adavosertib in adults with advanced solid tumors that have a missing or broken SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. Researchers want to see if it can shrink tumors or keep them stable for at least 6 months.
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could a High-Fat diet help cancer immunotherapy work better?
Disease control TerminatedThis early-phase trial is testing whether a ketogenic diet (low carbs, high fat) can safely help immunotherapy drugs work better in people with advanced melanoma or kidney cancer. About 60 participants will follow the diet while receiving standard immunotherapy. The main goals ar…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug duo takes on tough cancers
Disease control OngoingThis early-stage trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people whose prostate, bladder, or kidney cancer has spread. The main goals are to find the safest dose and see what side effects occur. About 65 participants will receive both drugs t…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo aims to outsmart Hard-to-Treat kidney cancer
Disease control OngoingThis phase II trial tests whether adding the immunotherapy drug atezolizumab to the standard drug cabozantinib helps people with advanced papillary kidney cancer live longer without their disease getting worse. About 200 participants will receive either cabozantinib alone or cabo…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to starve and attack tumors in advanced cancers
Disease control OngoingThis early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors like melanoma, colorectal, ovarian, and kidney cance…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail shows promise for Hard-to-Treat urinary cancers
Disease control OngoingThis early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo shows promise in shrinking advanced kidney tumors before surgery
Disease control OngoingThis study tests whether giving two drugs—lenvatinib and pembrolizumab—before surgery can shrink tumors in people with locally advanced kidney cancer that hasn't spread to other organs. About 18 participants will receive the combination for 12 weeks before their operation. The go…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Could a tropical berry boost immunotherapy for kidney cancer?
Disease control OngoingThis early-phase trial tests whether adding camu camu, a prebiotic fruit, to standard immunotherapy (nivolumab and ipilimumab) is safe and can improve treatment for advanced kidney cancer. About 31 people with metastatic clear-cell or sarcomatoid kidney cancer will receive the co…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Radiation may replace drugs for some kidney cancer patients
Disease control TerminatedThis phase 2 trial tests whether high-precision radiation (SBRT) can control kidney cancer that has spread to a few spots in the body. The goal is to see if radiation alone can delay or replace the need for systemic drug therapy. The study involves 123 participants and includes b…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Gut bacteria booster may help kidney cancer drugs work better
Disease control OngoingThis early-phase trial is testing whether adding a probiotic called CBM588 to the standard combination of cabozantinib and nivolumab can improve treatment for advanced or metastatic kidney cancer. The probiotic is designed to restore helpful gut bacteria that may help the immune …
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for kidney cancer: which drug combo works best after immunotherapy fails?
Disease control OngoingThis study tests two different drug treatments in people with advanced kidney cancer that has spread and continued to grow despite prior immunotherapy. About 90 participants will receive either a combination of lenvatinib and everolimus or cabozantinib alone. The goal is to see w…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug cocktail targets rare, aggressive kidney cancer
Disease control OngoingThis phase II trial is testing whether combining the targeted drug ixazomib with two chemotherapy drugs (gemcitabine and doxorubicin) can shrink tumors or stop them from growing in patients with a rare and aggressive kidney cancer called renal medullary carcinoma. The study enrol…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Head-to-Head drug battle for rare kidney cancer
Disease control OngoingThis study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug is safer and more effective at slowing cancer growth. About 32 to 84 participa…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New immune cell therapy trial for advanced cancers withdrawn before starting
Disease control TerminatedThis early-stage trial aimed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. STIL101 is made from a patient's own immune cells taken from their tumor, …
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can a smartphone app ease the mind for kidney cancer patients?
Symptom relief OngoingThis study is testing whether a smartphone app that teaches mindfulness can help people with advanced kidney cancer cope with their illness. The trial will enroll 21 patients who are already receiving immunotherapy and have moderate to high fear of their cancer returning. The mai…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Wheat germ supplement studied for immune boost in advanced cancer
Knowledge-focused TerminatedThis study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jul 02, 2026 02:00 UTC